Get the StoQuant digest — free
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks.
Email only, no account needed. See a sample digest.
BEAT vs TAK — Stock Comparison
Compare BEAT and TAK side-by-side on StoQuant: BEAT Q-Score 2 vs TAK 44; analyst signal 61 vs 75. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- BEAT — HeartBeam, Inc. · Health Care · market cap $32M · Q-Score verdict Strong Sell (2.0, grade F) · analyst signal 61/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: valuation 75/100, earnings quality 51/100 · weakest signals: competitive moat 4/100, technicals 2/100. Full BEAT research.
- TAK — Takeda Pharmaceutical Company Limited · Health Care · market cap $57.60B · Q-Score verdict Hold (44.0, grade C) · analyst signal 75/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 75/100, valuation 73/100 · weakest signals: technicals 48/100. Full TAK research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: BEAT research · TAK research. Sign in to StoQuant to run live comparisons for any tickers.